. . . . . . . . . . "a(CHEBI:troglitazone) -> path(SDIS:\"muscle glucose import\")" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "Addition of a sulfonylurea to metformin therapy gives an additive glucose- lowering effect (102, 103,149). Similarly, addition of metformin to sulfonylurea therapy gives an additive response, both with respect to glucose-lowering (101, 103, 149-152) and lipid-lowering (91, 103) effects the elevated fasting plasma glucose level is caused by incomplete suppression of basal hepatic glucose production by sulfonylurea or metformin Figure 1. Pathogenesis of type 2 diabetes mellitus. Sites of action of oral agents are indicated. A negative sign indicates inhibition; a positive sign indicates stimulation." . . "Selventa" . . . . "2014-07-03T14:29:48.171+02:00"^^ . . .